A novel selective inverse agonist of the CB2 receptor as a radiolabeled tool compound for kinetic binding studies.

Andrea Martella, Huub Sijben, Arne C. Rufer, Uwe Grether, Juergen Fingerle, Christoph Ullmer, Thomas Hartung, Adriaan P. IJzerman, Mario van der Stelt and Laura H. Heitman



Sup. Fig.1. *Filtration binding comparison between [^{3}H]RO6957022 and [^{3}H]CP55,940.* Total (**TB**) and non-specific (**NSB**) binding, were determined in the absence or presence of AM630 (10 μM), respectively (**A**). Similar assay conditions (i.e. Tris-HCl 50 mM, pH 7.4 (25^{o}C) and 0.1% BSA) were used for both radioligands, except for $MgCl_2$ (5 mM) added to the [^{3}H]CP55,940 samples. Data are shown as mean ± S.E.M. of three independent experiments performed in duplicate; statistical significance was determined by student *t*-test (*** $p \leq 0.001$). Please note the differences in specific activity for both radioligands ([^{3}H]RO6957022, 83.7 Ci/mmol, and [^{3}H]CP55,940, 150.2 Ci/mmol). Prolonged binding association experiment with 3 nM [^{3}H]RO6957022 interacting with CHO-K1_hCB_2 membranes at 25°C (**B**). Data are shown as mean ± S.E.M. of three independent experiments.